New pain drug hits target, misses CNS

The fast-growing drug discovery arm of the Italian Institute of Technology has published a preclinical study in which a novel pain therapy with front-line potential was able to deliver a shot of pain relief in tissue while detouring the central nervous system. The Drug Discovery and Development unit, dubbed D3, said that URB937 works in peripheral tissue by inhibiting the enzyme fatty acid amide hydrolase (FAAH). The drug controls pain and inflammation at the specific site it originates in by boosting levels of anandamide. Report

Suggested Articles

All 12 members of an FDA advisory committee voted to recommend the approval of teprotumumab for a rare, autoimmune eye disease.

Early data out of former Fierce 15 winner Gritstone Oncology have been heralded as a big win for the early-stage biotech by analysts.

Biogen will drop work on gosuranemab in progressive supranuclear palsy but continue on in Alzheimer's.